United States Kidney Function Tests Market Annual Growth 2025: AI Integration, Diagnostic Advances and Market Trends | F. Hoffmann-La Roche Ltd, Nova Biomedical, Quest Diagnostics

According to DataM Intelligence Comprehensive Report has released its latest report on the "Kidney Function Tests Market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/kidney-function-tests-market?kb

Recent Trials

A new multinational clinical trial, EASi-KIDNEY, has begun recruiting participants in Oxford to test a promising treatment for chronic kidney disease (CKD). The trial will evaluate whether the drug vicadrostat (BI 690517), combined with the existing treatment empagliflozin, can better slow CKD progression, reduce hospitalizations for heart failure, and lower cardiovascular deaths.

With around 11,000 participants across 15-20 countries, this is one of the largest CKD trials ever conducted. CKD affects 1 in 10 adults worldwide and often leads to kidney failure or heart complications. Current treatments help but don't fully stop disease worsening, so new options like vicadrostat are urgently needed.

Developed by Boehringer Ingelheim, vicadrostat showed promising results in earlier trials by significantly reducing a key kidney damage marker. This trial also uses a cutting-edge trial management system called Cantata, designed to streamline and improve large-scale clinical research.

Participants will be followed for 3-4 years, with results expected by 2028/2029. This groundbreaking study aims to offer new hope to millions living with CKD.

Major Key Player:

F. Hoffmann-La Roche Ltd, Nova Biomedical, Quest Diagnostics, 77 Elektronika Kft, ACON Laboratories, Inc.

Roche and KlinRisk Launch First AI-Based Kidney Function Risk Tool with CE Mark

Roche, in partnership with KlinRisk, has received CE marking for the world's first AI-driven risk stratification tool to assess progressive kidney function decline. This tool, part of Roche's new Chronic Kidney Disease (CKD) algorithm panel on the navify® Algorithm Suite, supports care across all CKD stages, including early detection in adults with diabetes or hypertension.

CKD affects over 700 million people globally and is often undiagnosed in its early stages. Early intervention can slow disease progression and reduce cardiovascular risks. The Kidney Klinrisk Algorithm uses machine learning to analyze routine blood and urine tests, helping clinicians make precise treatment decisions.

Integrated into Roche's cloud-based navify platform, the panel offers seamless access to risk assessments and aligns with clinical guidelines. Currently available in Europe and the UK, it will expand to the US, Middle East, and Asia.

This innovative solution marks a major step in Roche's digital health strategy to address the growing global CKD burden. For more information, healthcare professionals can visit navify.com.

Swiss pharma company Roche has developed a new AI-powered tool to evaluate kidney function, which has successfully received the European CE marking of conformity. This Chronic Kidney Disease algorithm panel is now available in Europe and the UK, with plans to launch in the US, Middle East, and Asia in the future. Roche is integrating this tool into its Navify digital platform, designed to streamline workflows for laboratories and clinics.

Founded in 1896 in Basel by Fritz Hoffmann-La Roche, the Roche Group was among the first industrial medicine manufacturers and has a long history of groundbreaking medical products. Today, Roche operates globally, holding strong market positions in cancer drugs and diagnostics. In 2024, the company reported revenues of CHF 60.5 billion ($76 billion) and a net profit of CHF 9.2 billion.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/kidney-function-tests-market?kb

Latest M&A

Key players like Abbott, Roche, Thermo Fisher Scientific, and QIAGEN are actively engaged in research and acquisitions to expand diagnostic capabilities and innovative kidney function testing solutions.​

M&A activities include acquisitions of molecular diagnostics firms and partnerships for AI-driven chronic kidney disease (CKD) risk assessment tools.​

Roche recently received CE Mark for its AI-based Kidney Klinrisk Algorithm panel, aiding early risk assessment and management of CKD.​

CareDx announced the launch of HistoMapTM Kidney, a tissue-based molecular test enhancing kidney transplant diagnostics, underscoring precision medicine advances

Key Segments:

By Product Type
Drip Irrigation Systems - 55%: preferred for water efficiency and precision in various crop types.

Sprinkler Irrigation Systems - 30%: widely used for uniform water distribution in large-scale farming.

Mechanized Irrigation Systems - 15%: mainly deployed in extensive field crops for labor-saving benefits.

By Crop Type
Field Crops - 40%: largest share due to vast acreage and irrigation needs of staple grains and cereals.

Vegetables - 25%: high-value crops with growing adoption of efficient irrigation methods.

Plantation Crops - 15%: significant in tropical regions where plantations require regular irrigation.

By Application
Open Field Cultivation - 70%: dominant due to large-scale farming across diverse geographies.

Greenhouse Hydroponics - 20%: rapidly growing for controlled-environment high-value crop production.

Greenhouse Soil - 10%: smaller share focused on traditional protected cultivation methods.

Buy Now & Get 30% OFF - (Grab 50% OFF on 2+ reports) @ https://www.datamintelligence.com/buy-now-page?report=kidney-function-tests-market?kb

FDA 510(k) Approvals and IVD Market Expansion

FDA 510(k) clearances are accelerating the availability of innovative in vitro diagnostics (IVDs) for kidney disease. This regulatory support is fueling market growth and adoption of new diagnostic technologies.

Rising Diabetes and Hypertension-driven Testing Demand

Increasing prevalence of diabetes and hypertension is driving demand for kidney function testing globally. Early and frequent testing in these high-risk groups helps prevent CKD progression and complications.

Have any Query We Will Provide in Detailed @ https://www.datamintelligence.com/enquiry/kidney-function-tests-market?kb

Chronic Kidney Disease (CKD) Diagnostic Innovations

Recent advancements in CKD diagnostics focus on early detection and risk prediction using AI and biomarker-based tools. These innovations aim to improve patient outcomes by enabling timely interventions.

Serum Creatinine, eGFR, and Urine Albumin Testing

Serum creatinine and estimated glomerular filtration rate (eGFR) are key indicators of kidney function, while urine albumin tests detect kidney damage. Together, they form the cornerstone of CKD diagnosis and monitoring.

Point-of-care and Laboratory-based Diagnostic Systems

Point-of-care testing offers rapid, onsite kidney function assessment, improving accessibility and patient management. Laboratory-based systems provide high-precision analysis critical for comprehensive diagnostics.

Get 2-Day Free Trial + 50% OFF DataM Subscription@ https://www.datamintelligence.com/reports-subscription?kb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.